NCT05152459 is a Phase 1, PHASE2 clinical trial of Tazemetostat in Recurrent Follicular Lymphoma, sponsored by City of Hope Medical Center.

Who is sponsoring NCT05152459?

NCT05152459 is sponsored by City of Hope Medical Center.

What drugs are being tested in NCT05152459?

Interventions in NCT05152459: Tazemetostat, Ublituximab, Umbralisib.

What condition does NCT05152459 study?

NCT05152459 studies Recurrent Follicular Lymphoma, Refractory Follicular Lymphoma.

Is NCT05152459 still recruiting?

NCT05152459 is currently withdrawn. Last updated 31 May 2023.

Last reviewed 2023-05-31 · How we verify

NCT05152459

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Tazemetostat in Combination With Umbralisib and Ublituximab for the Treatment Relapsed or Refractory Follicular Lymphoma

Withdrawn Phase 1, PHASE2 Last updated 31 May 2023

What this trial tests

Phase 1, PHASE2 trial testing Tazemetostat in Recurrent Follicular Lymphoma. Withdrawn.

Timeline

1 May 2023

Primary endpoint
15 December 2024

15 December 2024

Quick facts

Lead sponsor	City of Hope Medical Center
Phase	Phase 1, PHASE2
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Start date	1 May 2023
Primary completion	15 December 2024
Estimated completion	15 December 2024

Drugs / interventions tested

Tazemetostat (tazemetostat) — full drug profile →
Ublituximab — full drug profile →
Umbralisib — full drug profile →

Conditions studied

Recurrent Follicular Lymphoma — all drugs for Recurrent Follicular Lymphoma →
Refractory Follicular Lymphoma — all drugs for Refractory Follicular Lymphoma →

Sponsor

City of Hope Medical Center

Who can join

18 and older, any sex, with Recurrent Follicular Lymphoma or Refractory Follicular Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This phase I/II trial tests the safety, side effects, and best dose of tazemetostat and umbralisib and whether tazemetostat in combination with umbralisib and ublituximab works to shrink tumors in patients with follicular lymphoma that has come back (relapsed) or does not respond to treatment (refractor). Tazemetostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Umbralisib may help block the formation of growths that may become cancer. Ublituximab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Giving tazemetostat in combination with umbralisib and ublituximab may work better in treating follicular lymphoma.

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

Regulatory T cells in homeostasis and disease: molecular mechanisms and therapeutic potential.
Wang L, Liang Y, Zhao C, Ma P, et al · · 2025 · cited 26× · PMID 41087343 · DOI 10.1038/s41392-025-02326-4
Novel insights into histone lysine methyltransferases in cancer therapy: From epigenetic regulation to selective drugs.
Liao Q, Yang J, Ge S, Chai P, et al · · 2023 · cited 19× · PMID 36908859 · DOI 10.1016/j.jpha.2022.11.009
Critical Roles of Polycomb Repressive Complexes in Transcription and Cancer.
Dong GJ, Xu JL, Qi YR, Yuan ZQ, et al · · 2022 · cited 14× · PMID 36076977 · DOI 10.3390/ijms23179574
The Status and Prospects of Epigenetics in the Treatment of Lymphoma.
Liu J, Li JN, Wu H, Liu P. · · 2022 · cited 10× · PMID 35463343 · DOI 10.3389/fonc.2022.874645
A Promising Future for Precision Epigenetic Therapy for Follicular and Diffuse Large B-Cell Lymphoma?
Chung C. · · 2022 · cited 5× · PMID 35959380 · DOI 10.2147/blctt.s282247
WNT signaling in cancer: molecular mechanisms and potential therapies.
Liang J, Pan Y, Yang J, Zeng D, et al · · 2025 · cited 2× · PMID 41120801 · DOI 10.1186/s43556-025-00327-x
The role of <i>EZH2</i> dysregulation in the pathogenesis of B-cell lymphomas and its implications as a target therapy.
Candelaria M. · · 2026 · PMID 42211521 · DOI 10.3389/fonc.2026.1843273

Verify or expand the search:

Other trials of Tazemetostat

Trials testing the same drug.

NCT06575686 — Epcoritamab and Tazemetostat for the Treatment of Relapsed or Refractory Grade I-IIIa Follicular Lymphoma · Phase 2 · suspended
NCT06692452 — Tazemetostat Plus CHOP in 1L T-cell Lymphoma · Phase 2 · withdrawn
NCT06242834 — Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following ASCT or CAR T-cell Therapy in Patients With Aggres · Phase 2 · active not recruiting
NCT05983965 — Study of Tazemetostat in Lymphoid Malignancies · Phase 1 · terminated
NCT05151588 — Induction Chemotherapy and Tazemetostat for Locally Advanced SMARCB1-deficient Sinonasal Carcinoma · Phase 2 · not yet recruiting

Other recruiting trials for Recurrent Follicular Lymphoma

Currently open trials in the same condition.

NCT06948786 — Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL Tri · Phase 2 · recruiting
NCT06712810 — Q702 for the Treatment of Patients With Hematologic Malignancies · Phase 1 · recruiting
NCT06191887 — B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide · Phase 1 · recruiting
NCT05453396 — Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies · Phase 2 · recruiting
NCT05627245 — Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Tr · Phase 1 · active not recruiting

Other City of Hope Medical Center trials

Trials by the same sponsor.

NCT07365306 — Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant · Phase 2 · not yet recruiting
NCT07218692 — RP2 and Tivozanib for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy · Phase 2 · not yet recruiting
NCT07363408 — Ivonescimab and ADG126, Alone, and in Combination With Leucovorin and Fluorouracil or FOLFIRI Regimen for the Treatment · Phase 1 · not yet recruiting
NCT07226102 — Virtual Mental Health Intervention to Address Fear of Progression for Women With High Risk or Stage III-IV Gynecologic o · NA · withdrawn
NCT07225855 — Geriatric Assessment and Management for Older Adults Undergoing Chemotherapy and Radiation Therapy for Head and Neck Can · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05152459 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by City of Hope Medical Center
Last refreshed: 31 May 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05152459.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing